Physician profile
Alexander Evens
NPI 1114144649
$153,255.85
in general payments reported to CMS, 2019-2025
10 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99K · 2020: $16K · 2021: $1,968 · 2022: $11K · 2023: $12K · 2024: $274 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Travel and Lodging: $4,452 · Food and Beverage: $984 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,720.00 |
| Travel and Lodging | $4,452.37 |
| Food and Beverage | $984.14 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $141,094.39 | 2019-2025 | Zerbaxa, Recarbrio |
| Tetraphase Pharmaceuticals, INC. | $11,384.64 | 2019-2020 | |
| Coloplast Corp | $259.82 | 2024 | |
| Shionogi INC | $232.71 | 2021 | |
| Glaxosmithkline, LLC. | $124.94 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $55.20 | 2020-2022 | |
| Pfizer INC. | $30.54 | 2025 | |
| Viiv Healthcare Company | $26.39 | 2022-2024 | Cabenuva |
| Ibsa Pharma INC. | $24.03 | 2019 | |
| Gilead Sciences, INC. | $23.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Evens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.